Flagship’s initial contribution to Harbinger Health is $50 million.
Dr. Hahn, an oncologist, served as FDA commissioner from 2019 to 2021. Before that, he served as chief medical executive at MD Anderson Cancer Center in Houston.
“Harbinger Health is poised to redefine our approach to oncology, moving beyond cancer ‘staging’ and toward early detection that enables the diagnosis and treatment of cancer and ultimately to effectively reduce morbidity and mortality associated with the disease,” Dr. Hahn said in a statement.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
